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Abstract Desmoplakin is a ubiquitous component of
desmosomes and desmosome-like structures, such as the
cardiomyocyte area composita. Two major isoforms, des-
moplakin I (DSPI) and desmoplakin II (DSPII) are encoded
by alternative mRNA transcripts differentially spliced from
the same gene. The resulting proteins are identical in amino
acid sequence with the exception that DSPII contains only
one third of the central alpha-helical rod domain present in
DSPI. Here we describe a novel minor isoform of
desmoplakin that is also produced by alternative splicing
of the desmoplakin gene and that we name desmoplakin Ia
(DSPIa). DSPIa is an alternatively spliced DSPI mRNA
with a unique splice donor site that is 90% homologous to
and downstream of the DSPII specific donor. The resulting
DSPIa mRNA is in-frame and encodes a protein that has a
central alpha-helical rod domain of intermediate size and
that is 156 amino acids larger than DSPII and 443 amino
acids smaller than DSPI. We demonstrate, through recom-
binant expression and short interfering RNA knockdown,
that the DSPIa protein is readily detectable, albeit at
substantially lower levels than the dominant isoforms,
DSPI and DSPII. DSPIa mRNA has a similar tissue
distribution to that of DSPI and of DSPII.
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Introduction
Desmoplakin (DSP) is a key junctional protein necessary for
the morphogenesis and integrity of epithelial and vascular
tissues, being a linker protein providing attachment for
cytoskeletal elements such as intermediate filaments (IFs;
Getsios et al. 2004). DSP ablation in mice results in an
embryonic lethal phenotype (Gallicano et al. 1998), whereas
conditional targeting to the epidermis leads to severe trauma-
induced intercellular separation (Vasioukhin et al. 2001).
Human mutations in the DSP gene can result in a range of
clinical phenotypes (Cabral and South 2009); from striate
palmoplantar keratoderma (Armstrong et al. 1999; Whittock
et al. 1999), a mild skin condition, to sudden death from
heart defects (Norgett et al. 2000, 2006; Uzumcu et al.
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2006), through to early lethality as a result of devastating
skin blistering and subsequent water loss (Jonkman et al.
2005). DSP is a ubiquitous component of desmosomes and
desmosome-like structures, such as the cardiomyocyte area
composita (Angst et al. 1990; Franke et al. 1982, 2006). Two
major isoforms, desmoplakin I (DSPI) and desmoplakin II
(DSPII) are encoded by alternative mRNA transcripts
differentially spliced from the same gene (Green et al.
1990). Although usually expressed together, DSPI is the
predominant isoform in heart (Angst et al. 1990; Uzumcu et
al. 2006). DSPI and DSPII differ only in the size of the
central alpha-helical rod domain, DSPII having two thirds
fewer amino acids within this domain (Green et al. 1990).
Human mutation leading to DSPI ablation while leaving
DSPII intact results in severe arrhythmogenic right ventric-
ular cardiomyopathy (ARVC) and early heart failure coupled
with a mild skin phenotype of woolly hair and palmoplantar
keratoderma in a single patient aged 4 years. These data
reveal the importance of DSPI in heart tissue but highlight
the ability of DSPII to support early heart development and
to maintain skin homeostasis in inter-follicular epidermis
(Uzumcu et al. 2006).
Here, we described the identification and character-
isation of a novel human DSP isoform, DSPIa. DSPIa is
expressed as a result of an in-frame alternative splice donor
site within the DSPI gene. DSPIa mRNA encodes a protein
identical to DSPI and DSPII with the exception of the
central alpha-helical rod domain, which is of intermediate
size, being 156 amino acids larger than DSPII and 443
amino acids smaller than DSPI. This new isoform has been
previously overlooked presumably because of similarities
in molecular weight and a much reduced expression level
compared with DSPI and DSPII. We describe the tissue
distribution of DSPIa, showing it to be similar to that of
DSPI and of DSPII, and demonstrate that DSPIa is
detected in protein lysates from epidermal cells and heart
tissue.
Materials and methods
Reverse transcription with polymerase chain reaction
RNA was isolated from frozen skin sections by using the
RNAeasy mini kit (Qiagen, Calif., USA) and from cultured
cells at 70%–90% confluency by using the RNA-Bee
reagent (AMS Biotechnology, Spain) according to the
manufacturers’ specifications. cDNA was generated by
using M-MLV reverse transcription (RT; Promega, Calif.,
USA). RT-polymerase chain reaction (RT-PCR) for
expression profiling of DSP isoforms in a range of tissues
was carried out on normal skin cDNA isolated as
described and on Human Multiple Tissue cDNA panel 1
and Human Cardiovascular Multiple Tissues cDNA panel
(BD Biosciences, N.J., USA). The G3PDH (glyceraldehyde-
3-phosphate dehydrogenase) gene was amplified as a control
of cDNA abundance according to the manufacturer’s speci-
fications. Primers, which amplified cDNA corresponding to
DSPI, DSPIa and DSPII isoforms, were as follows: DSPIF,
5′ CTTGGAACTAAGGAGCCAG; DSPIaF, 5′ GCTTGA
TAGACTTTCAAGGG; DSPIIF, GATCGAAGTTTTG
GAAGAGG; DSPR, CCACCTGAGTACACTGATTC.
Quantitative PCR
Human liver and aorta total RNA was purchased from
Clontech (BD Biosciences) and human ventricle and atrium
total RNA was purchased from AMS Biotechnology
Europe (Abingdon, UK). cDNA was constructed as
described. Real-time quantitative PCR was performed by
using the MiniOpticon detection system (Bio-Rad, UK) and
the DyNAmo SYBR Green qPCR kit (Finnzymes, Finland).
DSP isoform-specific primers were as described above.
EF1alpha or B2M were used as reference genes. Cycling
conditions were according to the manufacturer’s instructions.
Relative quantification was established by defining the
difference between the reference and target cycle threshold
values for each sample.
Immunoblotting
Small fragments of redundant atrium tissue were obtained
during cardiac surgery and transported to the laboratory in
dry ice. These small fragments were solubilised into an
appropriate volume of 0.1 M TRIS-HCl pH 6.8, 0.2 M
dithiothreitol, 4% (w/v) SDS, 0.2% (w/v) bromophenol
blue and 20% (v/v) glycerol and subsequently boiled for
5 min before resolution on NuPAGE Novex 3%–8%
TRIS-acetate Mini gels according to the manufacturer’s
specifications (Invitrogen, The Netherlands). Whole-cell
protein extracts were prepared from cells lysed in 0.125 M
TRIS-HCl pH 6.8, 4% (w/v) SDS, 20% (v/v) glycerol,
0.001% (w/v) bromophenol and 1.44 M β-mercaptoethanol,
boiled for 5 min and resolved on SDS-PAGE as described.
The primary antibody used was 11-5F (mouse monoclonal
anti-DSPI and DSPII), a generous gift from David Garrod
(Parrish et al. 1987).
Recombinant DSPIa expression
DSPIa was cloned from primary human keratinocyte RNA
by using standard molecular biology techniques. The use of
the pBabe-puro retroviral vector (Morgenstern and Land
1990) and phoenix packaging system (Kinsella and Nolan
1996) to introduce full length DSPIa was as described
elsewhere (South et al. 2003).
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Transfections with short interfering RNA
Isoform-specific short interfering RNAs (siRNAs) were
designed by using the custom siRNA design tool from
Thermo Fisher Scientific (Waltham, Mass., USA) according
to the manufacturer’s specifications. siRNA sequences
targeting DSPI/DSPIa were as follows: si2, ATAAGGA
GATCGAGAGACT; si3, GGCCTGTGGCTCTGAGATA;
si4, AGATAGAACTGAAGCAGGT. siRNA sequences
targeting DSPI were as follows: siDSPI 1, GAGCTTATCT
GAAGAAATA; siDSPI 2, CGAACAGAGGAGAGCG
TAA. The siRNA designated as siI/II, which targets all
three isoforms, was published previously (Wan et al. 2007).
Transient transfections of HaCaT cells were performed
according to the DharmaFECT general transfection proto-
col (Thermo Fisher Scientific, UK) for a 6-well plate
format. Briefly, 2×105 cells per well of a 6-well dish were
seeded and incubated in antibiotic-free medium containing
fetal bovine serum, at 37°C, for 24 h prior to siRNA
transfection. In separate polystyrene tubes, 100 nM siRNA
(final concentration) and 6 μl DharmaFECT 1 were mixed
in serum- and antibiotic-free media and incubated at room
temperature for 5 min. The siRNA-containing medium
was added to the tube containing the DharmaFECT 1
reagent and these contents were mixed and incubated for
20 min at room temperature. Serum-containing media was
added to the mix and the cells were incubated in this
siRNA-containing media for 4 days and subsequently
prepared for Western blot. Cells transfected with a pool of
four non-targeting siRNAs (on target plus siControl non-
targeting pool) and cells incubated with DharmaFECT 1
transfection reagent only (mock) were used as negative
controls.
Results
RT-PCR amplification of a shorter DSPI cDNA
While cloning DSPI, we amplified a shorter than expected
cDNA product by using DSPI-specific PCR primers.
Direct sequencing revealed this PCR product was
1329 bp shorter than DSPI but corresponded to the DSPI
sequence. Alignment analysis showed that this shorter
cDNA had been generated by splicing involving the exon
24 splice acceptor (common to DSPI and DSPII) and a
previously unidentified splice donor within exon 23 of
DSPI. The spliced DSPI sequence was in-frame and
potentially coded for a desmoplakin protein intermediate
in size between DSPI and DSPII. We named this cDNA
sequence DSPIa. Figure 1a shows the organisation of the
DSP gene at exons 23-24 for DSPI, DSPII and the novel
DSPIa mRNA.
DSPIa utilises a donor splice site 90% homologous
to DSPII and is detected in ESTs from prostate cancer cell
line DU-145
Sequence analysis demonstrated that the DSPIa donor
splice site is 90% homologous to the exon 23 donor site
of DSPII (Whittock et al. 1999; Fig. 1a). Splice analysis of
the 3000-bp region spanning the end of exon 23 and the
beginning of exon 24 (see Fig. 1a) predicted DSPII and
DSPIa to harbour the two most efficient splice donors with
equal or highly similar prediction scores (Figs. 1b, S1a).
Interestingly, neither of the splice prediction software
packages that we used identified the DSPI donor site by
using default settings (Figs. 1b, S1a). Reducing the cut-off
of detection did eventually identify the DSPI donor site but
the sequence gave a considerably lower value than DSPII,
DSPIa and other potential splice donor sites within this
region (Fig. S1b, data not shown).
In order to establish whether DSPIa was present in the
EST database (dbEST; Boguski et al. 1993), we searched
for DSP sequences by using the BLAST 2.2.22 megablast
program (accessed from http://blast.ncbi.nlm.nih.gov/Blast.
cgi on 17-02-2010; Zhang et al. 2000). Using 50 bp
spanning each of the three isoform unique exon-exon
junctions, we identified 36 separate human EST entries
for DSPI, five separate human entries for DSPII and one
human entry for DSPIa. The prostate cancer cell line EST
homologous to DSPIa (accession AI525952) was of poor
sequence quality but displayed 86% homology over 342 bp
spanning the DSPIa exon-exon boundary by using the
BLAST 2.2.22 blastn program (accessed on 17-02-2010;
Altschul et al. 1997). Continuous homology between this
EST and DSPI or DSPII did not extend across exon-exon
boundaries demonstrating that this EST represented DSPIa
and that DSPIa is expressed in the prostate cancer cell line
DU-145. Figure 1c depicts the number of human EST
identified by searching dbEST with the corresponding
sequences.
DSPIa tissue distribution is similar to that of DSPI
and of DSPII
To identify the extent of DSPIa expression in various human
tissues, we designed a DSP isoform-specific RT-PCR
(Fig. 2a). Using this RT-PCR assay, we examined the
expression of DSPIa by using multiple tissue cDNA panels
and demonstrated that DSPIa expression was similar to that
of DSPI and of DSPII but, surprisingly, was the only isoform
detected in the aorta (Fig. 2b, c).
In order to verify our findings in the aorta and to
examine the relative level of DSPIa in cultured keratino-
cytes, epithelial and heart tissues, we used quantitative PCR
(Q-PCR) and total RNA-derived cDNA to show that DSPIa
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relative to DSPI levels are similar when comparing
epidermal keratinocyte cells and cell lines (ratio: 3–7 per
relative 100 DSPI) but that the relative level of DSPIa in
simple epithelial tissue (liver) and heart was lower (ratio:
0.1–2 per relative 100 DSPI; Fig. 2d). Using this
approach, we were able to detect DSPI and DSPIa in the
aorta and show that the expression of both these DSP
isoforms was significantly lower compared with other
heart compartments (Fig. 2e).
DSPIa is expressed in epidermal keratinocytes and heart
tissue
Because of the size and similarity of DSP proteins, we
speculated that DSPIa might have previously been over-
looked in Western blotting because of co-migration and
relative abundance. We therefore resolved total protein
lysates from cultured human epidermal keratinocytes and
human atrium tissue on 3%–8% gradient TRIS-Acetate gels
for a considerably longer time than we would normally.
Immunoblotting with a specific DSP antibody identified a
faint immunoreactive band of the expected size for DSPIa
(Fig. 3a). In order to confirm that this protein was indeed
DSPIa, we expressed DSPIa in A293 phoenix cells and the
epidermal keratinocyte cell line, HaCaT. Recombinant
DSPIa migrated at a distance corresponding to the faint
immunoreactive band in HaCaT cells (Fig. 3b).
siRNA knockdown with sequences specific to DSPI
and DSPIa efficiently target DSPIa
To confirm further the existence of detectable levels of DSPIa,
we used siRNA specifically to inhibit the mRNA of DSPI,
DSPI and DSPIa and all three isoforms. siRNAs si2, si3 and
si4 targeting DSPI and DSPIa (Fig. S2) significantly reduced
the level of both corresponding proteins (Fig. 3c), whereas
siRNA targeting DSPI only (Fig. S2) did not effect the levels
of DSPIa (Fig. 3d). All three isoforms were downregulated
with siRNA siI/II, which targets the 5′ end of DSP (Fig. 3d).
These data demonstrate that all immunoreactive bands are
DSP-specific and that only the knockdown of DSPI does not
effect DSPIa expression.
Fig. 1 Alternative splice prediction and expressed sequence tag (EST)
analysis of DSP isoform-specific mRNA. a Organisation of the DSP
gene at exons 23–24 for DSPI, DSPII and the novel DSPIa splice
variant. The sequences of three splice donors in exon 23 that produce
the different splice isoforms are shown (red shared nucleotides). b
Splice donor analysis of 3000 bp of sequence spanning intron 23 of the
DSP gene, indicated in a, (NNSPLICE version 0.9 accessed via http://
www.fruitfly.org/seq_tools/splice.html; Reese et al. 1997) identifies the
splice donor sites used by DSPII and DSPIa (grey) but not DSPI. c
Representation of DSP splice variants showing ESTs found in the NCBI
database; 5′ and 3′ regions (purple) are represented by 102 and 99 ESTs,
respectively. The DSPIa- and DSPII-specific junctions (yellow/green
and orange/green) are spanned by 1 and 5 ESTs, respectively. The
corresponding DSPI-specific junctions are represented by 37 (yellow)
and 31 (orange) ESTs, respectively. The DSPI-specific exon 23/24
junction (green) is represented by 36 ESTs. Each coloured square
comprises 25 bp each side of the dashed line
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Fig. 2 DSPIa mRNA expres-
sion profile is similar to that of
DSPI and of DSPII. a Left
Genomic organisation of exons
23–24 of DSPI, DSPII and the
novel DSPIa isoform showing
primers used specifically to
amplify and distinguish between
the different isoforms. The
reverse primer (DSPR, grey) is
common to all isoforms. Three
different forward primers
(DSPIF, green; DSPIaF, red;
DSPIIF, blue) were designed
specifically to amplify DSPI
(179 bp), DSPIa (383 bp) and
DSPII (530 bp), respectively.
Right RT-PCR products and
respective negative water con-
trols amplified from DSPI (lanes
1, 2), DSPIa (lanes 3, 4) and
DSPII (lanes 5, 6) RNA from
primary NHK (M molecular
weight marker). b, c Specific
amplification of the various DSP
transcripts across a range of
tissues in human multiple tissue
cDNA panels and in normal skin
and HaCaT and K1 keratinocyte
cell lines. DSPIa (383 bp) is
expressed throughout the major-
ity of epithelial tissues, normal
skin and keratinocyte cell lines
with similar expression patterns
to that of DSPI (179 bp) and of
DSPII (530 bp). DSPIa is also
expressed in cardiovascular
tissue but is the only DSP
isoform detected in the aorta.
Primers to amplify the G3PDH
gene (983 bp according to
NM_002046.3) were used as a
control of cDNA abundance
(Water negative control). d, e
SYBR Green quantitative
RT-PCR with forward primers
DSPIF, DSPIaF and DSPIIF and
the reverse primer DSPIR was
performed to amplify DSPI,
DSPIa and DSPII. d NHK,
HaCaT and K1 keratinocytes,
liver, aorta, atrium and ventricle
expression levels of all DSP
isoforms relative to DSPI
(normalised within each sample).
Error bars indicate mean±SEM,
minimum of n=3 in each case.
e Relative levels of mRNA
expression for each isoform are
shown, comparing cultured
primary keratinocytes with liver
and heart. All values are
normalised to NHK DSPI. All
samples are human. Error bars
indicate mean±SEM, minimum
of n=3 in each case
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Discussion
Pre-mRNA splicing is a mechanism of post-transcriptional
regulation of gene expression by which non-coding introns
are excised and exons are joined to form a mature mRNA
transcript. Alternative pre-mRNA splicing is thought to occur
in approximately 75% of all human genes (Johnson et al.
2003) and, by this mechanism, human cells are able to
synthesise over 90,000 proteins from approximately 26,000
coding genes (Ast 2004). Many of these alternative splice
variants are differentially expressed according to tissue type
and developmental stage. Alternative splicing involves
sequential phosphodiester transfer reactions that are cata-
lysed by a large ribonucleoprotein complex. Three consensus
sequences within each intron are required for splicing to
occur; 5′ and 3′ splice sites (donor and acceptor sites,
respectively) that flank each intron, and a branch point that is
located more than 18 nucleotides upstream of the acceptor
site and more than 48 nucleotides downstream of the donor
site (Matlin et al. 2005). Here, we identify a previously
undescribed DSP isoform, DSPIa, which is produced by
alternative splicing of the DSP gene. Given that DSPIa
shares its acceptor site with all isoforms of DSP and that its
donor splice site shares 90% homology with DSPII, differing
only in the 10th 3′ base, we speculate that the branch points
differ between DSPII and DSPIa. The possibility neverthe-
less exists that the branch point is shared and that DSPII is
the major splice variant because of efficiencies of the
spliceosome at the most 5′ sequence but our finding of
DSPIa in heart tissue in the absence of detectable DSPII
(Fig. 3a) suggests a unique branch point. Following on from
this logic, it is also likely that separate branch points direct
the variable tissue expression of DSPI and DSPII.
Our Q-PCR data show that we are able to detect all DSP
isoforms in all tissues tested with the exception of the aorta
in which DSPII is below the threshold of detection, data in
agreement with our original RT-PCR panel screen (Fig. 2c, d).
This is surprising given that, so far, no DSP protein has
been detected in junctions of the vascular endothelium of
human vessels, with the exception of the complexus
adhaerentes identified in the lymph node sinus (Moll et
al. 2009). Such junctions have also been identified in the
cultured human umbilical vein endothelial cell line
(Valiron et al. 1996). Our finding of extremely low levels
of DSP in aorta RNA suggests that the sensitive Q-PCR
methodology is able to detect low levels of mRNA
transcripts either regulated in a post-transcriptional man-
ner or contaminating RNA from a separate compartment.
Fig. 3 DSPIa is expressed in epidermal keratinocytes and human
atrium tissue. a Western blot of total proteins from HaCaT cells (H)
and normal human atrium (A). The predicted molecular weight of each
protein is indicated left (in kDa [KDa]). DSPIa is observed in HaCaT
cells, together with DSPI and DSPII. Expression of DSPI and low
levels of DSPIa are observed in the normal human atrium, whereas
DSPII is barely detectable in this tissue. b Phoenix cells were
transiently transfected with a pBabe-GFP control vector (GFP) and
the pBabe-DSPIa construct (DSPIa). Recombinant DSPIa expression
is observed in pBabe-DSPIa transfected cells at approximately
279 KDa. HaCaT cells transduced with the pBabe-DSPIa construct
(DSPIa) show expression of recombinant DSPIa at higher levels than
those of the endogenous DSPIa band in pBabe-GFP-transduced cells
(GFP). Higher exposure of the same blot (right) shows recombinant
DSPIa proteins migrate alongside endogenous DSPIa protein. Vincu-
lin (117 KDa) was used as a loading control. c Western blot of total
lysates from HaCaT cells transfected with 100 nM of each siRNA (si2,
si3, si4) designed to target DSPI/DSPIa. Endogenous DSPI and DSPIa
are downregulated with siRNAs si2-4 (Mock cells incubated with
DharmaFECT 1 transfection reagent only). d Western blot of whole
cell lysates from HaCaT cells transduced with pBabe-DSPIa construct.
DSPIa is downregulated with siRNAs that target the predicted DSPIa
(siI, siI/II) sequence but not with siRNAs that are DSPI-specific
(siDSPI 1/2)
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The ability to detect DSPI by Q-PCR but not by RT-PCR
probably reflects template complexity; the RT-PCR cDNA
panels used in Fig. 2b, c are produced from polyadeny-
lated mRNA and are at low concentrations (total input
approximately 5 ng), whereas the Q-PCR assay cDNA are
constructed from total RNA at a concentration of around
400 ng. The lack of detectable DSPII is curious but, notably,
PCR is dependent on the efficiency of primer binding
coupled with template complexity and we cannot compare
absolute levels between the different DSP isoform Q-PCR
assays relative to control (Bustin 2000). A definitive
demonstration of expression relies on protein detection,
which in itself is dependent on antibody specificity. Here, we
demonstrate the detection of DSPIa by using an antibody
raised against a common DSP epitope (Parrish et al. 1987)
and, although a different protein conformation may influence
recognition, we feel that this is unlikely. By this method, we
have detected DSPIa protein in cultured keratinocytes and
heart tissue and no DSPII in heart tissue (Fig. 3a).
DSPIa has not previously been described, presumably
because of multiple factors chiefly resulting from the low
level of expression relative to DSPI and DSPII (which
would lead to a reduced number of EST spanning intron 23
of the DSPIa gene, for example) but also from the difficulty
in resolving DSPII protein from DSPIa by using standard
Western blotting techniques. Indeed, our ability to resolve
DSPIa is clearly dependent upon a number of as yet
undetermined parameters; occasionally, DSPIa is particu-
larly prominent (for example, Fig. 3c) and, at other times, it
is less pronounced (Fig. 3a). However, DSPIa is clearly a
minor isoform of DSP that is expressed in a wide range of
human tissues, with DSPIa being translated into a protein
that is identical to DSPI and DSPII in both the N and C
terminal portions but contains only half of the DSPI alpha
helical rod domain. Lack of evidence for DSPIa protein in
the extensive documentation of DSP can be attributed to the
widespread use of non-human tissue (Mueller and Franke
1983) and cell lines (Green et al. 1991) and insufficient
protein resolution. We are, however, tempted to speculate
that DSPIa has been previously identified by using Western
blotting of protein lysates from FaDu cells (human upper
respiratory tract tumour line) by Angst and colleagues
(1990) but, again, the resolution and quantity of protein was
not sufficient for conclusive evidence.
The function of the various domains of DSP has been
extensively investigated (Bornslaeger et al. 1996; Fontao et
al. 2003; Green et al. 1990, 1992; Kouklis et al. 1994;
Kowalczyk et al. 1994; Meng et al. 1997; Smith and Fuchs
1998; Stappenbeck et al. 1993, 1994; Stappenbeck and
Green 1992; Vasioukhin et al. 2001). The C-terminal domain
of DSP is responsible for mediating interactions with various
types of IFs: vimentin in meninges and dendritic cells of
lymph nodes, desmin in the myocardium and a variety of
keratins in epithelial tissues (Fontao et al. 2003; Kouklis et
al. 1994; Meng et al. 1997; Stappenbeck et al. 1993;
Stappenbeck and Green 1992). The N-terminal plakin
domain of DSP is important for targeting DSP to the
junctional plaque through interactions with the armadillo
proteins plakoglobin and plakophilin (Bornslaeger et al.
2001; Kowalczyk et al. 1997, 1999) and DSP has also been
shown to be able to bind itself through this domain (Smith
and Fuchs 1998). However, whereas interactions with
binding partners are known to be facilitated by the N- and
C-terminal domains of DSP, the rod domain is thought only
to be important for self-association (Green et al. 1990;
O’Keefe et al. 1989). DSP isolated from pig tongue has
provided evidence that DSPI can homo-dimerise in solution,
whereas DSPII remains monomeric (O’Keefe et al. 1989).
However, the rod domains of both DSPI and DSPII are
predicted to form homophilic coiled-coil dimers (Green et al.
1990; Virata et al. 1992). Such higher order aggregates of
DSP are thought to form a filamentous network that interacts
with other desmosomal plaque proteins between the mem-
brane and IFs (Getsios et al. 2004). North et al. (1999) have
proposed, based on the immunogold labelling of the N- and
C- termini revealing consistent spatial localisation in tissues
expressing both DSPI and DSPII, that DSPII governs the
thickness of the inner dense plaque and that DSPI is folded
within the plaque. This logic would translate to DSPIa but
the functional consequences of shortening the rod domain
remain unknown. Interestingly, the detection of DSPIa in
heart tissue raises the possibility that DSP protein with a
shorter rod domain, regardless of overall amounts, might be
necessary for desmosomal integrity. Notably, however, the
assembly of desmosomal components in vitro is possible
with DSPI and, therefore, DSPII and DSPIa might simply be
“structural accessories” (Bornslaeger et al. 2001).
Nine human mutations have so far been reported within
the rod domain of DSP. Two of these mutations (p.R1113X
and p.R1934X) affect all three isoforms; another three
(p.R1255K, p.R1267X and p.N1324fsZ23) affect DSPI and
DSPIa and four (p.R1775I, p.K1583R, p.L1654P and
p.Q1446X) affect only DSPI while leaving DSPIa and DSPII
intact (Bolling and Jonkman 2009). Three of the mutations
affecting only DSPI are missense mutations causing domi-
nant ARVC, whereas the single nonsense mutation affecting
only DSPI, p.Q1446X, causes recessive cardio-cutaneous
disease when inherited with another nonsense mutation,
p.Q673X, which affects all isoforms (Asimaki et al. 2009).
This combination of mutations is predicted to lead to
complete ablation of DSP expression from one allele
(p.Q673X) and ablation of DSPI only, allowing expression of
DSPII and DSPIa from the other allele (p.Q1446X). This
contrasts with the homozygous p.R1267X nonsense
mutation, which leads to complete absence of both DSPI
and DSPIa, leaving DSPII intact, and resulting in
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recessive cardio-cutaneous disease (Uzumcu et al. 2006).
In this case (p.R1267X/p.R1267X), the cutaneous pheno-
type is relatively mild (compared with p.Q673X/p.
Q1446X) presumably because of normal DSPII expression
(which is haplo-insufficient in p.Q673X/p.Q1446X and
results in more severe cutaneous disease). Interestingly,
the cardiac phenotype might be considered more severe in
p.R1267X/p.R1267X with cardiac failure at age 4 years
compared with cardiac failure at age 9 years in the p.Q673X/
p.Q1446X case and therefore we are tempted to speculate that
these data show that expression of DSPIa, although not
capable of rescuing the cardiac phenotype, can influence its
severity and positively contributes towards cardiac cohesion.
The ratio between DSPI and DSPII varies among the
different tissues and different cell types; DSPII, which is
abundantly expressed in complex epithelial tissues, is
expressed at lower levels in cells derived from some other
epithelial tissues such as epidermoid carcinoma (vulva) and
human bladder carcinoma (transitional epithelium; Angst et
al. 1990) and in the heart (Uzumcu et al. 2006). We show
here that the relative levels of DSPI, DSPII and DSPIa are
consistent in keratinocyte-derived cells and that DSPIa, like
DSPII relative levels, is decreased in the liver and heart
compared with keratinocytes.
The majority of desmosomal genes are alternatively
spliced and little is known about the role of some of these
splice isoforms, such as DSC “b” proteins or indeed DSPII.
A large volume of research has been published based on
recombinant DSPI and whether DSPII or DSPIa has any
differential biological role in cell junction formation and
signalling remains to be seen. Further work will be
necessary to investigate the importance and function of
these isoforms.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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